Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NTRA-9620
- Development stage
- Phase 3
- Lead developer
- Nutrinia
- Modality
- Peptides
- Administration
- Oral
01
Overview
NTRA-9620 is an oral insulin formulation developed for gastrointestinal rehabilitation and post-resection bowel adaptation. It is specifically designed to enhance intestinal adaptation in infants with Short Bowel Syndrome (SBS) following surgical resection. The drug acts locally in the gut without systemic exposure, stimulating intestinal growth, cell maturation, and enzyme expression. This mechanism aims to improve nutrient absorption, reduce reliance on parenteral nutrition support, and increase enteral nutrition intake in patients with SBS.
- Other names
- oral insulin humanrecombinant human insulin
02
Targets
INSR (Insulin receptor)ODC1 (Ornithine decarboxylase)PTK (Protein-Tyrosine Kinase)
Beyond the preview
Go deeper on NTRA-9620.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NTRA-9620.